Prostaglandin E
COVID-19
D-dimer
Leukotriene B4
Prostaglandin E2
SARS-CoV-2
Viral Load
Journal
Prostaglandins & other lipid mediators
ISSN: 1098-8823
Titre abrégé: Prostaglandins Other Lipid Mediat
Pays: United States
ID NLM: 9808648
Informations de publication
Date de publication:
10 Feb 2024
10 Feb 2024
Historique:
received:
17
08
2023
revised:
16
12
2023
accepted:
09
02
2024
medline:
13
2
2024
pubmed:
13
2
2024
entrez:
12
2
2024
Statut:
aheadofprint
Résumé
Prostaglandin E This cross-sectional study involved non-infected (n=10) individuals and COVID-19 patients classified as cured (n=13), oligosymptomatic (n=29), severe (n=15) or deceased (n=11). Levels of D-dimer a, known COVID-19 severity marker, PGE PGE Our data indicate that PGE
Sections du résumé
BACKGROUND
BACKGROUND
Prostaglandin E
METHODS
METHODS
This cross-sectional study involved non-infected (n=10) individuals and COVID-19 patients classified as cured (n=13), oligosymptomatic (n=29), severe (n=15) or deceased (n=11). Levels of D-dimer a, known COVID-19 severity marker, PGE
RESULTS
RESULTS
PGE
CONCLUSIONS
CONCLUSIONS
Our data indicate that PGE
Identifiants
pubmed: 38346573
pii: S1098-8823(24)00014-5
doi: 10.1016/j.prostaglandins.2024.106820
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106820Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.